ScholarLens Back to search
2013•Medical Innovation of ChinaRequires access

The Atorvastatin Affect Serum Matrix Metalloproteinase-9 Level in Acute Coronary Syndrome Patients

LI Dao-yua

Open publisher page 0 citations

Abstract

Objective:To observe serum matrix metalloproteinase-9(MMP-9)level in the acute coronary syndrome(ACS)patients after atorvastatin therapy. Method:90 ACS patients for the study group,unstable angina pectoris 45 cases(UAP group)and acute myocardial infarction 45cases(AMI group),were admitted to hospital.except for the basic treatment,each patient was taken 20mg atorvastatin one day,and was measured the serum MMP-9 level before and after treatment. 30 patients healthy control group was measured serum MMP-9 level. Result:Study group serum MMP-9levels was significantly higher than that in the control group(P0.01);Both of the UAP group and AMI group serum level of MMP-9 was significantly lower than pretreatment(P0.01).Conclusion:Atorvastatin significantly reduces serum MMP-9 level in patients with ACS,and plays a role in atherosclerotic plaque stability.

About this research paper

What this paper is about

Objective:To observe serum matrix metalloproteinase-9(MMP-9)level in the acute coronary syndrome(ACS)patients after atorvastatin therapy. Method:90 ACS patients for the study group,unstable angina pectoris 45 cases(UAP group)and acute myocardial infarction 45cases(AMI group),were admitted to hospital.except for the basic treatment,each patient was taken 20mg atorvastatin one day,and was measured the serum MMP-9 level before and after treatment. 30 patients healthy control group was measured serum MMP-9 level. Result:Study group serum MMP-9levels was significantly higher than that in the control group(P0.01);Both of the UAP group and AMI group serum level of MMP-9 was significantly lower than pretreatment(P0.01).Conclusion:Atorvastatin significantly reduces serum MMP-9 level in patients with ACS,and plays a role in atherosclerotic plaque stability.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To observe serum matrix metalloproteinase-9(MMP-9)level in the acute coronary syndrome(ACS)patients after atorvastatin therapy. Method:90 ACS patients for the study group,unstable angina pectoris 45 cases(UAP group)and acute myocardial infarction 45cases(AMI group),were admitted to hospital.except for the basic treatment,each patient was taken 20mg atorvastatin one day,and was measured the serum MMP-9 level before and after treatment. 30 patients healthy control group was measured serum MMP-9 level. Result:Study group serum MMP-9levels was significantly higher than that in the control group(P0.01);Both of the UAP group and AMI group serum level of MMP-9 was significantly lower than pretreatment(P0.01).Conclusion:Atorvastatin significantly reduces serum MMP-9 level in patients with ACS,and plays a role in atherosclerotic plaque stability.

Key concepts: Medicine, Atorvastatin, Acute coronary syndrome, Unstable angina, Matrix metalloproteinase 9, Internal medicine, Myocardial infarction, Matrix metalloproteinase

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The Atorvastatin Affect Serum Matrix Metalloproteinase-9 Level in Acute Coronary Syndrome Patients — Research Paper | ScholarLens